Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 

Celgene Corp., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Short-term borrowings and current portion of long-term debt 1.41 0.00 1.78 0.00 3.49
Accounts payable 1.18 1.01 0.88 0.89 1.14
Rebates, distributor chargebacks and distributor services 3.12 2.70 2.00 1.36 1.34
Compensation 1.10 1.19 1.47 1.31 1.83
Clinical trial costs and grants 1.34 2.06 1.22 0.94 1.09
Litigation-related loss contingency 0.00 0.00 0.71 0.00 0.00
Interest 0.67 0.57 0.60 0.63 0.34
Sales, use, value added, and other taxes 0.19 0.20 0.36 0.26 0.38
Milestones payable 0.00 0.21 0.00 0.00 0.00
Success payment liability 0.20 0.00 0.00 0.00 0.00
Short-term contingent consideration and success payments 0.17 0.00 0.17 0.40 0.20
Royalties, license fees and collaboration agreements 0.32 0.17 0.00 0.00 0.00
Deferred tax liability 0.00 0.00 0.00 0.00 0.76
Other 1.31 1.27 1.01 1.20 1.36
Accrued expenses and other current liabilities 8.42% 8.37% 7.53% 6.09% 7.31%
Income taxes payable 0.22 0.28 0.15 0.07 0.07
Current portion of deferred revenue 0.21 0.25 0.20 0.22 0.16
Current liabilities 11.43% 9.91% 10.54% 7.28% 12.18%
Deferred revenue, net of current portion 0.21 0.11 0.10 0.11 0.16
Income taxes payable 6.17 8.26 1.50 1.20 1.57
Deferred income tax liabilities 7.76 4.40 0.00 1.40 3.20
Other non-current tax liabilities 0.00 0.00 8.97 9.31 0.00
Contingent consideration 0.29 0.27 5.14 5.22 7.18
Deferred compensation and long-term incentives 0.68 0.80 0.77 0.63 0.87
Contingent value rights 0.05 0.14 0.16 0.19 0.79
Derivative contracts 0.06 0.44 0.00 0.00 0.00
Other 0.26 0.16 0.24 0.11 0.29
Other non-current liabilities 1.34% 1.80% 6.31% 6.15% 9.12%
Long-term debt, net of discount, excluding current portion 55.72 52.55 49.09 52.68 36.13
Non-current liabilities 71.20% 67.13% 65.97% 70.84% 50.19%
Total liabilities 82.64% 77.04% 76.50% 78.12% 62.37%
Preferred stock, $.01 par value per share; none outstanding 0.00 0.00 0.00 0.00 0.00
Common stock, $.01 par value per share 0.03 0.03 0.03 0.03 0.05
Common stock in treasury, at cost -74.23 -67.16 -57.97 -51.94 -61.70
Additional paid-in capital 42.22 45.80 44.07 41.10 56.67
Retained earnings 49.49 43.33 35.87 29.85 37.33
Accumulated other comprehensive income (loss) -0.14 0.95 1.49 2.84 5.28
Stockholders’ equity 17.36% 22.96% 23.50% 21.88% 37.63%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Short-term Borrowings and Current Portion of Long-term Debt
The proportion of short-term borrowings and current portion of long-term debt relative to total liabilities and stockholders’ equity declined from 3.49% in 2014 to 1.41% in 2018, with intermittent missing data in 2015 and 2017. This suggests a reduction in reliance on short-term debt components over the period.
Accounts Payable
Accounts payable as a percentage of total liabilities and stockholders’ equity displayed minor fluctuations, decreasing from 1.14% in 2014 to 0.88% in 2016, then increasing modestly to 1.18% by 2018. This indicates relatively stable payables management with a slight upward trend towards the end of the period.
Rebates, Distributor Chargebacks, and Distributor Services
This category saw a consistent increase, rising from 1.34% in 2014 to 3.12% in 2018, nearly tripling over five years. This growth highlights an increasing impact of rebates and distributor-related charges on the company's liabilities.
Compensation
Compensation liabilities decreased steadily from 1.83% in 2014 to 1.10% in 2018, indicating a downward trend in accrued compensation-related obligations.
Clinical Trial Costs and Grants
The percentage increased initially from 1.09% in 2014, reaching a peak of 2.06% in 2017, but declined to 1.34% in 2018. This suggests a temporary intensification in clinical trial expenditures followed by a partial reduction.
Litigation-related Loss Contingency
Data is only reported for 2016, where it accounted for 0.71% of the total, indicating a specific legal contingency impact that year with no further information available.
Interest
Interest liabilities experienced a moderate increase from 0.34% in 2014 to 0.67% in 2018, reflecting slightly higher interest-related obligations relative to total financing.
Sales, Use, Value Added, and Other Taxes
These taxes decreased from 0.38% in 2014 to 0.19% in 2018, showing improved tax-related liability management or changes in tax obligations during the period.
Milestones Payable and Success Payment Liability
Milestones payable appeared in 2017 at 0.21%, and success payment liability appeared in 2018 at 0.20%, indicating emerging liabilities related to milestone and success-based agreements in the later years.
Short-term Contingent Consideration and Success Payments
This liability fluctuated, starting at 0.20% in 2014, peaking at 0.40% in 2015, and settling back to 0.17% in 2018. The inconsistency suggests variable contingent payment expectations.
Royalties, License Fees, and Collaboration Agreements
Reported only in 2017 and 2018, increasing from 0.17% to 0.32%. This reflects an increasing importance of these liabilities during the final two years.
Deferred Tax Liability
Notable deferred tax liabilities were recorded only in 2014 at 0.76%, with no reported values afterward, indicating a discontinuation or reclassification of this item.
Other Current Liabilities
Generally stable between 1.2% and 1.36%, with slight cyclical variations over the period.
Accrued Expenses and Other Current Liabilities
This category showed an increasing trend from 7.31% in 2014 to 8.42% in 2018, suggesting gradually rising accrued obligations over the period.
Income Taxes Payable (Current and Non-current)
Current income taxes payable increased notably from 0.07% in 2014 to a peak of 0.28% in 2017 before slightly decreasing to 0.22% in 2018. Non-current income taxes payable rose significantly in 2017 to 8.26% from 1.2% in 2015, before declining to 6.17% in 2018. This indicates volatility and increased tax liabilities, particularly in non-current categories.
Deferred Income Tax Liabilities
This liability decreased sharply from 3.20% in 2014 to 1.40% in 2015, was unreported in 2016, then surged to 7.76% by 2018, indicating fluctuations and eventual significant growth in deferred income tax obligations.
Other Non-current Tax Liabilities
Reported only in 2015 and 2016, these liabilities remained high at approximately 9% before disappearing from reported data, implying a shift or resolution in this area.
Contingent Consideration
There was a significant decline from 7.18% in 2014 to 0.29% in 2018, indicating that contingent consideration liabilities were considerably reduced over the years.
Deferred Compensation and Long-term Incentives
This liability remained relatively stable, ranging from 0.63% to 0.87%, without any clear trend.
Contingent Value Rights
The proportion steadily decreased from 0.79% in 2014 to 0.05% in 2018, suggesting diminishing obligations related to contingent value rights.
Derivative Contracts
Data was absent for the initial years; in 2017, derivative contracts accounted for 0.44%, dropping to 0.06% in 2018, indicating limited but declining exposure.
Other Non-current Liabilities
Displayed a substantial decrease from 9.12% in 2014 to 1.34% in 2018, indicating a significant reduction in this category of liabilities.
Long-term Debt, Net of Discount, Excluding Current Portion
This category consistently increased from 36.13% in 2014 to 55.72% in 2018, showing growing reliance on long-term debt financing.
Non-current Liabilities
Non-current liabilities increased significantly from 50.19% in 2014 to 71.20% in 2018, reflecting an overall growth in long-term obligations.
Total Liabilities
Total liabilities rose steadily from 62.37% in 2014 to 82.64% in 2018, indicating increasing leverage and debt accumulation relative to total capital.
Common Stock and Additional Paid-in Capital
The common stock share of total liabilities and equity remained negligible and stable around 0.03%-0.05%. Additional paid-in capital declined from 56.67% in 2014 to 42.22% in 2018, showing reductions in contributed capital relative to total liabilities and equity.
Treasury Stock
Common stock held in treasury increased negatively from -61.7% in 2014 to -74.23% in 2018, indicating growing treasury stock holdings that reduce overall equity.
Retained Earnings
Retained earnings increased from 37.33% in 2014 to 49.49% in 2018, reflecting an accumulation of earnings over time.
Accumulated Other Comprehensive Income (Loss)
This category decreased from 5.28% in 2014 to a negative value of -0.14% in 2018, indicating a decline and eventual loss in comprehensive income components.
Stockholders’ Equity
Stockholders’ equity as a percentage of total liabilities and equity declined considerably from 37.63% in 2014 to 17.36% in 2018, showing a reduced equity base relative to the overall capital structure.
Total Liabilities and Stockholders’ Equity
Remained constant at 100% as expected, serving as the basis for percentage calculations of all other items.